DJIA 16,960.57 -123.23 -0.72%
NASDAQ 4,449.56 -22.54 -0.50%
S&P 500 1,978.34 -9.64 -0.48%
market minute promo

Emergent BioSolutions (NYSE: EBS)

22.81 -0.13 (-0.57%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

EBS $22.81 -0.57%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $22.84
Previous Close $22.94
Daily Range $22.62 - $22.98
52-Week Range $16.85 - $28.48
Market Cap $853.3M
P/E Ratio 43.28
Dividend (Yield) $0.00 (0.0%)
Volume 142,396
Average Daily Volume 231,694
Current FY EPS $0.00

Sector

Healthcare

Industry

Drugs

Emergent BioSolutions (EBS) Description

Emergent BioSolutions makes the only FDA-approved anthrax vaccine. Website: http://www.emergentbiosolutions.com/

News & Commentary

You Shouldn't Ignore Gilead's Idelalisib

Gilead Sciences is widely known for its HIV drug portfolio and for its high-profile hep-C drug sofosbuvir. But it also has a potential winner with idelalisib, a blood cancer drug with a promising future.

Biodel Q2 Loss Wider Than Expected - Analyst Blog

Emergent BioSolutions Enters Oversold Territory (EBS)

Healthcare Stocks Adding to Day-Long Surge; Emergent BioSolutions Slumps After Street.com Downgrade

Sector Update: Healthcare

Shares Continue to fall on Emergent BioSolutions' Wider Loss - Analyst Blog

Emergent BioSolutions Inc Stock Downgraded (EBS)

Healthcare Stocks Nudging Back into the Green; Emergent BioSciences Declines After Q1 Miss, Weak Q2

Healthcare Stocks Nudging Back into the Green; Emergent BioSciences Declines After Q1 Miss, Weak Q2 Outlook

Sector Update: Healthcare

Notable Two Hundred Day Moving Average Cross - EBS

Emergent BioSolutions' (EBS) CEO Dan Abdun-Nabi on Q1 2014 Results - Earnings Call Transcript

See More EBS News...

EBS's Top Competitors

EBS $22.81 (-0.57%)
Current stock: EBS
AMGN $122.84 (0.47%)
Current stock: AMGN
GILD $89.84 (-0.77%)
Current stock: GILD
BIIB $335.45 (-0.40%)
Current stock: BIIB